華森製藥(002907.SZ)收到奧美沙坦酯氨氯地平片藥品補充申請批准通知書
格隆匯2月19日丨華森製藥(002907.SZ)公佈,公司已於2023年1月完成藥品生產許可證變更,並於近日收到國家藥品監督管理局核准簽發的關於奧美沙坦酯氨氯地平片的《藥品補充申請批准通知書》,標誌着該產品已完成藥品上市許可持有人變更工作,公司已成為其藥品上市許可持有人,公司將盡快開展市場營銷工作。
藥品適應症:用於治療原發性高血壓。本固定劑量複方適用於單用奧美沙坦酯或單用氨氯地平治療血壓控制效果不佳的成人患者。
本次公司獲得奧美沙坦酯氨氯地平片的《藥品補充申請批准通知書》併成為其上市許可持有人,有助於豐富公司產品管線,增加心腦血管領域的銷售品種,有利於公司的可持續發展。公司將盡快開展市場營銷工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.